CYP2B13 Inhibitors
CYP2B13 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the CYP2B13 enzyme, a member of the cytochrome P450 superfamily. CYP2B13, like other enzymes in this family, is involved in the oxidative metabolism of a diverse array of substrates, including endogenous molecules such as hormones and fatty acids, as well as exogenous substances like drugs and environmental chemicals. The primary function of CYP2B13 is to catalyze the monooxygenation of these substrates, a process that involves the incorporation of an oxygen atom into the substrate molecule, typically resulting in increased solubility and facilitating subsequent metabolic processes such as conjugation and excretion. This enzymatic activity plays a crucial role in maintaining the metabolic balance within cells, particularly in the liver, where most cytochrome P450 enzymes are highly expressed and active.
Inhibitors of CYP2B13 are designed to bind specifically to the active site of the enzyme, blocking its ability to catalyze the oxidation of its substrates. These inhibitors may work by occupying the enzyme's substrate-binding pocket, thus preventing the natural substrate from accessing the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The design and development of CYP2B13 inhibitors require a detailed understanding of the enzyme's three-dimensional structure, particularly the regions involved in substrate binding and catalysis. By inhibiting CYP2B13, researchers can explore its specific role in the metabolism of various compounds and how its activity integrates into the broader metabolic pathways governed by the cytochrome P450 superfamily. The study of CYP2B13 inhibitors provides valuable insights into the enzyme's substrate specificity, its role in the detoxification and biotransformation processes, and its interaction with other metabolic enzymes. This research contributes to a broader understanding of the functional diversity within the cytochrome P450 family and the critical roles these enzymes play in maintaining metabolic homeostasis and processing a wide range of chemical entities within biological systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ticlopidine Hydrochloride | 53885-35-1 | sc-205861 sc-205861A | 1 g 5 g | $32.00 $99.00 | 2 | |
Ticlopidine inhibits CYP2B13 through direct interaction, disrupting its heme binding and monooxygenase activities. This interference impairs the xenobiotic catabolic process and alters cellular responses. | ||||||
Thio-TEPA | 52-24-4 | sc-253693 | 1 g | $228.00 | ||
Thio-TEPA acts as a direct inhibitor of CYP2B13, modulating its heme binding and monooxygenase activities. This perturbation influences steroid metabolic processes, suggesting a potential regulatory role in steroid biosynthetic pathways. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine directly inhibits CYP2B13, impacting its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, indicating a role in cellular detoxification and response modulation. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine serves as a direct inhibitor of CYP2B13, affecting its heme binding and monooxygenase activities. This modulation influences xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram acts as a direct inhibitor of CYP2B13, interfering with its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, implicating a role in cellular detoxification mechanisms and response regulation. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole, a direct inhibitor of CYP2B13, disrupts its heme binding and monooxygenase activities. This interference extends to steroid metabolic processes, suggesting a potential role in regulating steroid biosynthesis. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 inhibits CYP2B13 directly, impacting its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Ritonavir serves as a direct inhibitor of CYP2B13, influencing its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $122.00 | 1 | |
Clopidogrel acts as a direct inhibitor of CYP2B13, disrupting its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
Efavirenz | 154598-52-4 | sc-207612 | 10 mg | $171.00 | 3 | |
Efavirenz, a direct inhibitor of CYP2B13, impacts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||